TY - JOUR
T1 - Effects of Age, Sex, Body Weight, and Quantity of Alcohol Consumption on Occurrence and Severity of Alcoholic Hepatitis
AU - Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium
AU - Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium
AU - Liangpunsakul, Suthat
AU - Puri, Puneet
AU - Shah, Vijay H.
AU - Kamath, Patrick
AU - Sanyal, Arun
AU - Urban, Thomas
AU - Ren, Xiaowei
AU - Katz, Barry
AU - Radaeva, Svetlana
AU - Chalasani, Naga
AU - Crabb, David W.
AU - Crabb, David
AU - Liangpunsakul, Suthat
AU - Katz, Barry
AU - Lourens, Spencer
AU - Borst, Andy
AU - Cook, Ryan
AU - Yu, Andy Qigui
AU - Nelson, David
AU - Saxena, Romil
AU - Cummings, Sherrie
AU - Comerford, Megan
AU - Edwards, Lakye
AU - Shah, Vijay
AU - Gores, Gregory
AU - Kamath, Patrick
AU - Verma, Vikas
AU - Wilder, Sarah
AU - Olofson, Amy
AU - Schimek, Amanda
AU - Sanyal, Arun
AU - Walker, Susan
AU - Raedeva, Svetlana
N1 - Funding Information:
The Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium was established with funding from the National Institutes of Health/National Institute of Alcohol Abuse and Alcoholism to study the pathogenesis and new treatments for alcoholic hepatitis. It consists of 3 academic centers in the United States: Indiana University (Indianapolis, IN), Mayo Clinic (Rochester, MN), and Virginia Commonwealth University (Richmond, VA). The Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium members at Indiana University (Indianapolis, IN) are as follows: David Crabb, MD, Naga Chalasani, MD, Suthat Liangpunsakul, MD, Barry Katz, PhD, Spencer Lourens, PhD, Andy Borst, BS, Ryan Cook, MPH, Andy Qigui Yu, PhD, David Nelson, PhD, Romil Saxena, MD, Sherrie Cummings, RN, Megan Comerford, BS, and Lakye Edwards, BS. The Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium members at Mayo Clinic (Rochester, MN) are as follows: Vijay Shah, MD, Gregory Gores, MD, Patrick Kamath, MD, Vikas Verma, PhD, Sarah Wilder, RN, BSN, Amy Olofson, RN, and Amanda Schimek, RN. The Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium members at Virginia Commonwealth University (Richmond, VA) are as follows: Arun Sanyal, MD, Puneet Puri, MD, and Susan Walker, RN, MSN. The Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium Scientific/Program Collaborator is Svetlana Raedeva, PhD (The National Institute of Alcohol Abuse and Alcoholism).
Funding Information:
Funding The Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium is supported by the National Institute on Alcohol Abuse and Alcoholism (5U01AA021883-04, 5U01AA021891-04, 5U01AA021788-04, and 5U01AA021840-04).
Publisher Copyright:
© 2016 AGA Institute
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background & Aims Only a minority of heavy drinking individuals develop alcoholic hepatitis (AH), for unclear reasons. We analyzed data from the Translational Research and Evolving Alcoholic Hepatitis Treatment cohort, consisting of subjects who drink heavily with normal results from liver tests (controls) and patients with AH. We examined risk factors for the development of AH including body mass index (BMI), drinking pattern and quantity, and sex. Methods We compared data from 145 patients with AH and 124 controls based on BMI when they joined the cohort; groups were matched for sex and race. Drinking patterns were assessed using the timeline followback method, the Alcohol Use Disorders Identification Test, and the National Institute of Alcohol Abuse and Alcoholism 6-question survey. We performed univariable and multivariable analyses to assess the effects of these factors and their interaction in increasing the risk for AH. We also explored the association between PNPLA3 variants and AH. Results Cases with AH were older (47 vs 44 y; P = .03). For nearly all measures of quantity of alcohol consumed or frequency of binge drinking, controls drank more heavily than cases with AH. We did not find an association between BMI, sex, drinking patterns, and the presence of AH. Age and BMI were independent predictors for the severity of AH. When we analyzed cases and controls of European ancestry, the PNPLA3 single-nucleotide polymorphism rs738409 was associated with risk for AH (odds ratio, 1.89; P = .007). Conclusions Compared with heavy drinkers without liver disease, subjects with AH consumed lower levels of alcohol and had less binge drinking, suggesting an increased sensitivity to the toxic effects of alcohol. The risk for AH may be associated with the PNPLA3 rs738409 polymorphism.
AB - Background & Aims Only a minority of heavy drinking individuals develop alcoholic hepatitis (AH), for unclear reasons. We analyzed data from the Translational Research and Evolving Alcoholic Hepatitis Treatment cohort, consisting of subjects who drink heavily with normal results from liver tests (controls) and patients with AH. We examined risk factors for the development of AH including body mass index (BMI), drinking pattern and quantity, and sex. Methods We compared data from 145 patients with AH and 124 controls based on BMI when they joined the cohort; groups were matched for sex and race. Drinking patterns were assessed using the timeline followback method, the Alcohol Use Disorders Identification Test, and the National Institute of Alcohol Abuse and Alcoholism 6-question survey. We performed univariable and multivariable analyses to assess the effects of these factors and their interaction in increasing the risk for AH. We also explored the association between PNPLA3 variants and AH. Results Cases with AH were older (47 vs 44 y; P = .03). For nearly all measures of quantity of alcohol consumed or frequency of binge drinking, controls drank more heavily than cases with AH. We did not find an association between BMI, sex, drinking patterns, and the presence of AH. Age and BMI were independent predictors for the severity of AH. When we analyzed cases and controls of European ancestry, the PNPLA3 single-nucleotide polymorphism rs738409 was associated with risk for AH (odds ratio, 1.89; P = .007). Conclusions Compared with heavy drinkers without liver disease, subjects with AH consumed lower levels of alcohol and had less binge drinking, suggesting an increased sensitivity to the toxic effects of alcohol. The risk for AH may be associated with the PNPLA3 rs738409 polymorphism.
KW - Alcohol Intake
KW - Alcoholic Hepatitis
KW - Body Weight
KW - Gender
KW - TLFB
KW - TREAT
UR - http://www.scopus.com/inward/record.url?scp=84992712509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992712509&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2016.05.041
DO - 10.1016/j.cgh.2016.05.041
M3 - Article
C2 - 27320325
AN - SCOPUS:84992712509
SN - 1542-3565
VL - 14
SP - 1831-1838.e3
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 12
ER -